Ascentage Pharma declares first patient dosed in APG-2575 trial
Category: #health  By Nikita Chaurasia  Date: 2019-07-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ascentage Pharma declares first patient dosed in APG-2575 trial

APG-2575 created by Ascentage Pharma is one of the rare Bcl-2 selective inhibitors in active clinical studies apart from Venetoclax.

Ascentage Pharma has reportedly announced that it has dosed the first patient in a phase I medical study of APG-2575, a new Bcl-2 selective inhibitor, for treating hematologic malignancies in China. The company also has a continuing multi-center phase I APG-2575 dose-escalation trial as a single agent in Australia and the United States. APG-2575 is anticipated to potentially be the first Bcl-2 inhibitor made in China.

For the record, APG-2575 is an innovative, orally managed Bcl-2 selective inhibitor. It is created to heal hematologic malignancies through selective blocking Bcl-2 to recreate the regular apoptosis process in cancer cells.

Reportedly, the founding member of the Bcl-2 family proteins is Bcl-2. The Bcl-2 family proteins are most prominent for their significant roles in regulating apoptosis by the development of heterodimers through pro-apoptotic proteins (BAD, BIM and many others). It is complicated to create a drug which affects Bcl-2 family protein due to the hydrophobic and very large Bcl-2 protein interfaces. The promoted Bcl-2 inhibitor venetoclax/ABT-199 accepted by the U.S. FDA in April 2016 has legalized the medical basis for more targeted drug development. APG-2575 created by Ascentage Pharma is one of the rare Bcl-2 selective inhibitors in active clinical studies apart from Venetoclax.

Sources claimed that the Phase I trial is created to evaluate the tolerance and safety of APG-2575 in patients enduring hematologic malignancies. The trial is also designed to check the recommended Phase II dose (RP2D) or maximal tolerated dose (MTD) of APG-2575. Patients with acute Non-Hodgkin's Lymphoma (NHL) and Acute Myelogenous Leukemia (AML) have been Included in this trial. Presently, the first enrolled patient has been medicated during the initial stage of dose-escalation.

Ascentage Pharma has reportedly released numerous preclinical research outcomes of APG-2575 during the annual meeting of 2019 American Association for Cancer Research (AACR). The results have shown the potential in combination therapy.

Source credit:

https://www.prnewswire.com/news-releases/ascentage-pharma-announces-first-patient-dosed-in-phase-i-clinical-trial-of-apg-2575-in-china-as-the-first-china-made-bcl-2-inhibitor-300884516.html

https://www.tullahomanews.com/news/business/ascentage-pharma-announces-first-patient-dosed-in-phase-i-clinical/article_8c4cdc27-db63-59f8-9ce9-dd301581f9fc.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial
Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial
By Nikita Chaurasia

Tmunity Therapeutics Inc., a clinical-stage biotherapeutics firm focused on advanced T-cell immunotherapy, has reportedly dosed the first patient in its Phase 1 CART-TnMUC1-01 clinical trial with TnMUC1 (Tn/STn glycoform of mucin 1) CAR-T (chimeric a...

Hyundai and Uber team up to develop all-electric flying taxis
Hyundai and Uber team up to develop all-electric flying taxis
By Nikita Chaurasia

In the midst of technological advancements increasing at a commendable pace, Uber’s flying taxi initiative seems to be edging closer to reality – the reality of establishing flying cars in the near future. The ride-hailing giant has appar...

BioXcel begins Phase 3 BXCL501 trial for treating SCZ & bipolar disorder
BioXcel begins Phase 3 BXCL501 trial for treating SCZ & bipolar disorder
By Nikita Chaurasia

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical firm leveraging artificial intelligence approaches to advance the next wave of medicines in immuno-oncology and neuroscience, has reportedly announced the initiation of its SERENITY progr...